Remifentanil

[1]

Why this is examined

Remifentanil is the only opioid whose offset is essentially independent of infusion duration. That single property underpins propofol–remifentanil TIVA, neuroanaesthesia with immediate wake-up testing, titratable analgesia in organ failure, and the classic exam trap of catastrophic rebound pain when the infusion stops without a transition plan [1][2][4].

Chemistry, receptor and potency

Remifentanil is a synthetic anilidopiperidine (phenylpiperidine) opioid with a methyl-ester side chain. It is a selective full agonist at the mu-opioid receptor, producing analgesia, respiratory depression, miosis, bradycardia and muscle rigidity like other pure mu agonists. Potency is similar to fentanyl (order of magnitude ~100 times morphine). It does not release histamine. [1]

The ester bond is the whole story: non-specific esterases in blood and tissues hydrolyse remifentanil to remifentanil acid, which has negligible clinical activity. Clearance is therefore: [1]

• independent of hepatic blood flow and CYP pathways for practical purposes
• independent of renal function for the parent drug
• not dependent on butyrylcholinesterase (pseudocholinesterase) — patients with suxamethonium apnoea still metabolise remifentanil [3]

Pharmacokinetics in numbers

Flat context-sensitive half-time — the graph to draw

Context-sensitive half-time (CSHT) is the time for plasma concentration to fall by 50% after stopping an infusion of a given duration. For fentanyl, alfentanil and sufentanil the curve climbs as peripheral compartments fill. For remifentanil the curve is a horizontal line near 3 to 4 minutes. That is why examiners ask you to sketch CSHT curves and point to remifentanil as the exception [1][4].

Offset is metabolic, not redistribution. After a single fentanyl bolus you wake partly because drug redistributes; after remifentanil you wake because the molecules are destroyed. [1]

Clinical use table (learnable)

Typical adult maintenance rates often sit in a broad band such as 0.05 to 0.5 microg/kg/min (or TCI target ranges per model library). State that you titrate to effect, reduce with hypnotic synergy, and know age adjustments — do not recite a single magic number as if universal. [1]

Acute tolerance and opioid-induced hyperalgesia

Within hours, remifentanil can produce acute tolerance and OIH so that the same surgical stimulus needs higher rates, and cessation unmasks a hyperalgesic patient [2]. Exam answer structure:

1. Anticipate it whenever infusion is more than brief.
2. Before stopping: long-acting opioid (e.g. morphine IV titrated) and/or regional block and/or ketamine anti-hyperalgesic dose and simple analgesics.
3. Time the long-acting drug so its peak covers remifentanil disappearance (often 20–30 minutes pre-end).
4. Do not "just give naloxone" for pain — that is wrong physiology. [1]

Adverse effects and immediate management

Comparison tables

Versus other phenylpiperidines

Versus morphine

Morphine is slow, long, hepatic with active morphine-6-glucuronide that accumulates in renal failure, and provides lasting post-op analgesia. Remifentanil is the opposite kinetic tool. They are partners (transition), not substitutes. [1]

Cost and stewardship

Remifentanil is expensive and needs a pump, training and a transition culture. Use it where its kinetics buy safety or surgical conditions; do not use it as default for every case if a simple fentanyl–volatile technique with regional would serve [5].

SAQ answer scaffold

1. Classify remifentanil and state receptor.
2. Describe esterase metabolism and metabolite activity.
3. Define CSHT and contrast remifentanil with fentanyl.
4. Give two clinical indications with dosing philosophy.
5. Detail transition analgesia and OIH.
6. List CVS and rigidity risks with management. [1]

Viva stem bank and model phrases

• "What is unique about remifentanil kinetics?" → "Non-specific esterase hydrolysis produces a context-sensitive half-time that remains about 3 to 4 minutes regardless of infusion duration."
• "How do you stop a remifentanil TIVA?" → "I do not simply switch it off. I ensure multimodal and a longer-acting opioid or regional analgesia is established about 20 to 30 minutes before the planned end, then taper the remifentanil as surgery finishes."
• "Is remifentanil safe in cholinesterase deficiency?" → "Yes for metabolism — it is not a butyrylcholinesterase substrate." [1]

Common traps

• Treating remifentanil like fentanyl boluses on the ward.
• No transition plan.
• Large rapid boluses causing rigidity and bradycardia.
• Confusing remifentanil with remimazolam.
• Claiming hepatic metabolism as primary clearance. [1]

[1] [1]

Red flags

[1]

References

1. [1]Kazokas D, et al. The Effects of Low-Dose Remimazolam Adjunct on Propofol-Remifentanil Anaesthesia in Day Case Gynaecological Surgery: A Retrospective Cohort Study Medicina (Kaunas), 2026.PMID 42356189
2. [2]Wang YM, et al. Feasibility and safety of an analgesia-first strategy without hypnotic sedatives in adult patients admitted to the intensive care unit after neurosurgical craniotomy: a protocol for a single-arm, single-center exploratory prospective study Front Med (Lausanne), 2026.PMID 42359072
3. [3]Rizopoulou S, et al. Variations in S-100Β and Neuron-Specific Enolase Levels During Functional Endoscopic Sinus Surgery Under Moderately Controlled Hypotension Using Four Distinct Anesthetic Protocols: A Randomized Controlled Study Medicina (Kaunas), 2026.PMID 42356019
4. [4]Ramesh S, et al. Integrated Advanced Monitoring and Target-Controlled Infusion Anesthesia in a Child With Arthrogryposis Multiplex Congenita Cureus, 2026.PMID 42359210
5. [5]Alnemri A, et al. Predictors of Unplanned Admission After Outpatient Rhytidectomy Aesthet Surg J, 2026.PMID 42322187
6. [6]Sun L, et al. Perioperative anesthetic management in pediatric patients with medically refractory pulmonary arterial hypertension undergoing surgical or transcatheter potts shunt: a retrospective case series BMC Anesthesiol, 2026.PMID 42304217